Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NT-101
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NexThera Files IND for Phase 1/2a Trial of NT-101 Eye Drop for Wet AMD
Details : NT-101 is a PDEF modulator peptide drug candidate, which is currently being evaluated for the treatment of patients with wet age-related macular degeneration.
Brand Name : NT-101
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 16, 2024
Lead Product(s) : NT-101
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?